Macrogenics Inc MGNX

NAS: MGNX | ISIN: US5560991094   30/04/2025
1,735 USD (+8,44%)
(+8,44%)   30/04/2025
Grafiek Macrogenics Inc Grafiek Macrogenics Inc

Macrogenics Inc in het nieuws

13 september 2024 · MacroGenics, Inc. (MGNX) Investors: September 24, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP · Persbericht

13 september 2024 · Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics Lawsuit - MGNX · Persbericht

12 september 2024 · INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenics · Persbericht

10 september 2024 · Shareholders that lost money on MacroGenics, Inc.(MGNX) should contact Levi & Korsinsky about pending Class Action - MGNX · Persbericht

7 september 2024 · MacroGenics, Inc. Investors Reminder: Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc. Shareholders of Deadline in Securities Fraud Class Action Lawsuit · Persbericht

6 september 2024 · Contact Levi & Korsinsky by September 24, 2024 Deadline to Join Class Action Against MacroGenics, Inc.(MGNX) · Persbericht

5 september 2024 · SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenics · Persbericht

3 september 2024 · Investors in MacroGenics, Inc. Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights - MGNX · Persbericht

1 september 2024 · Kessler Topaz Meltzer & Check, LLP Notifies MacroGenics, Inc. Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit · Persbericht

31 augustus 2024 · INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenics · Persbericht

Profiel Macrogenics Inc

Biotechnologie
Fabricage van farmaceutische preparaten
Gezondheidstechnologie
Productie

Website: www.macrogenics.com

Hoofdzetel: Rockville, Maryland vlag Verenigde Staten

CEO: Scott Koenig

Werknemers: 415

Mijn selecties